Literature DB >> 17631237

Herpes zoster and postherpetic neuralgia in older adults.

Kenneth Schmader1.   

Abstract

Herpes zoster (HZ) afflicts millions of older adults annually and causes significant suffering from acute and chronic pain, or postherpetic neuralgia (PHN). HZ is caused by the reactivation of varicella-zoster virus (VZV) in sensory ganglia in the setting of age, disease, and drug-related decline in cellular immunity. VZV-induced neuronal destruction and inflammation cause the pain, interference with activities of daily living, and reduced quality of life. The optimal treatment of HZ requires early antiviral therapy and pain management. For PHN, evidence-based pharmacotherapy can reduce pain burden. The zoster vaccine is effective in reducing pain burden and preventing HZ and PHN in older adults.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17631237      PMCID： PMC4859150          DOI： 10.1016/j.cger.2007.03.003

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN： 0749-0690            Impact factor:   3.076


  42 in total

1.  Acute pain in herpes zoster and its impact on health-related quality of life.

Authors:  Jennifer Katz; Edith M Cooper; Robert R Walther; Eugene W Sweeney; Robert H Dworkin
Journal:  Clin Infect Dis       Date:  2004-07-19       Impact factor: 9.079

2.  Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.

Authors:  Michael S Simberkoff; Robert D Arbeit; Gary R Johnson; Michael N Oxman; Kathy D Boardman; Heather M Williams; Myron J Levin; Kenneth E Schmader; Lawrence D Gelb; Susan Keay; Kathleen Neuzil; Richard N Greenberg; Marie R Griffin; Larry E Davis; Vicki A Morrison; Paula W Annunziato
Journal:  Ann Intern Med       Date:  2010-05-04       Impact factor: 25.391

3.  A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster.

Authors:  James D Berry; Karin Lottrup Petersen
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

4.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Authors:  Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

Review 5.  The varicella-zoster virus genome.

Authors:  Jeffrey I Cohen
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 6.  Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Authors:  Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

7.  The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults.

Authors:  Kenneth E Schmader; Richard Sloane; Carl Pieper; Paul M Coplan; Alexander Nikas; Patricia Saddier; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Heather M Williams; Michael N Oxman
Journal:  Clin J Pain       Date:  2007 Jul-Aug       Impact factor: 3.442

8.  A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.

Authors:  Ruth Harbecke; Michael N Oxman; Beth A Arnold; Charlotte Ip; Gary R Johnson; Myron J Levin; Lawrence D Gelb; Kenneth E Schmader; Stephen E Straus; Hui Wang; Peter F Wright; Constance T Pachucki; Anne A Gershon; Robert D Arbeit; Larry E Davis; Michael S Simberkoff; Adriana Weinberg; Heather M Williams; Carol Cheney; Luba Petrukhin; Katalin G Abraham; Alan Shaw; Susan Manoff; Joseph M Antonello; Tina Green; Yue Wang; Charles Tan; Paul M Keller
Journal:  J Med Virol       Date:  2009-07       Impact factor: 2.327

9.  A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.

Authors:  Robert H Dworkin; Richard L Barbano; Stephen K Tyring; Robert F Betts; Michael P McDermott; Janet Pennella-Vaughan; Gary J Bennett; Erhan Berber; John W Gnann; Carrie Irvine; Cornelia Kamp; Karl Kieburtz; Mitchell B Max; Kenneth E Schmader
Journal:  Pain       Date:  2009-02-04       Impact factor: 6.961

10.  Update on recommendations for use of herpes zoster vaccine.

Authors:  Craig M Hales; Rafael Harpaz; Ismael Ortega-Sanchez; Stephanie R Bialek
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-08-22       Impact factor: 17.586
View more
  13 in total

1.  Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

2.  In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.

Authors:  G Andrei; D Topalis; P Fiten; C McGuigan; J Balzarini; G Opdenakker; R Snoeck
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

3.  Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer.

Authors:  Michael J Boeckh; Ann M Arvin; Kathleen M Mullane; Luis H Camacho; Drew J Winston; Vicki A Morrison; Kimberly Hurtado; Jessie Durrand Hall; Lei Pang; Shu-Chih Su; Susan S Kaplan; Paula W Annunziato; Zoran Popmihajlov
Journal:  Open Forum Infect Dis       Date:  2020-06-02       Impact factor: 3.835

4.  Chronic medical conditions as risk factors for herpes zoster.

Authors:  Riduan M Joesoef; Rafael Harpaz; Jessica Leung; Stephanie R Bialek
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

5.  Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.

Authors:  Mark Ritchie; Hiltrud Liedgens; Mark Nuijten
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

6.  The role of social determinants in timely herpes zoster vaccination among older American adults.

Authors:  Sohul Shuvo; Tracy Hagemann; Kenneth Hohmeier; Chi-Yang Chiu; Sujith Ramachandran; Justin Gatwood
Journal:  Hum Vaccin Immunother       Date:  2021-01-30       Impact factor: 3.452

7.  The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Authors:  Robert W Johnson; Didier Bouhassira; George Kassianos; Alain Leplège; Kenneth E Schmader; Thomas Weinke
Journal:  BMC Med       Date:  2010-06-21       Impact factor: 8.775

8.  The Incidence and Risk of Herpes Zoster in Patients With Sleep Disorders: A Population-Based Cohort Study.

Authors:  Wei-Sheng Chung; Hsuan-Hung Lin; Nan-Cheng Cheng
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 9.  Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.

Authors:  Oliver Damm; Bernhard Ultsch; Johannes Horn; Rafael T Mikolajczyk; Wolfgang Greiner; Ole Wichmann
Journal:  BMC Public Health       Date:  2015-06-05       Impact factor: 3.295

Review 10.  Zoster vaccine live for the prevention of shingles in the elderly patient.

Authors:  Jamie Zussman; Lorraine Young
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.